Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered Entry - {财报副标题}

Live News

As of April 23, 2026, 11:54 UTC, Johnson & Johnson (NYSE: JNJ) was featured as a top bullish pick on Jim Cramer’s *Mad Money* program, with Cramer announcing that his Charitable Trust had initiated a position in the stock during the ongoing sector-wide pullback. Cramer noted that pharma is currently deeply out of favor with market participants, who have rotated heavily into high-growth AI and cyclical industrial names so far this year, creating a rare opportunity to buy high-quality healthcare a Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryVolume analysis adds a critical dimension to technical evaluations. Increased volume during price movements typically validates trends, whereas low volume may indicate temporary anomalies. Expert traders incorporate volume data into predictive models to enhance decision reliability.Combining technical indicators with broader market data can enhance decision-making. Each method provides a different perspective on price behavior.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryMarket anomalies can present strategic opportunities. Experts study unusual pricing behavior, divergences between correlated assets, and sudden shifts in liquidity to identify actionable trades with favorable risk-reward profiles.

Key Highlights

1. **Valuation Profile**: JNJ currently trades at 13.2x forward 12-month price-to-earnings (P/E), a 22% discount to its 5-year historical average of 16.9x, and an 18% discount to the large-cap pharma peer group average of 16.1x. The stock also offers a 3.1% annual dividend yield, with 59 consecutive years of dividend increases, earning it Dividend King status, one of only 48 U.S. public companies to hold the designation. 2. **Icotyde Catalyst**: Consensus sell-side estimates project Icotyde will Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryInvestors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Market participants increasingly appreciate the value of structured visualization. Graphs, heatmaps, and dashboards make it easier to identify trends, correlations, and anomalies in complex datasets.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryReal-time data also aids in risk management. Investors can set thresholds or stop-loss orders more effectively with timely information.

Expert Insights

Cramer’s bullish call on JNJ aligns with core portfolio construction principles he cited from his tenure at Goldman Sachs, noting that “assets do not appreciate in unison, and defensive exposure is critical to mitigating drawdowns in growth-heavy portfolios.” With a 5-year beta of 0.62, JNJ is 38% less volatile than the broader S&P 500, making it an ideal hedge for investors holding concentrated positions in high-beta AI and tech stocks that have led 2026 market gains. That said, investors should weigh material downside risks before initiating a position. JNJ’s top-selling immunology drug Stelara loses U.S. exclusivity in 2027, with consensus estimates projecting the loss of $2.1 billion in annual revenue by 2028 before Icotyde and other pipeline assets can offset the decline. Additionally, proposed U.S. drug pricing reforms could compress margins for JNJ’s top 10 selling products by an estimated 7% to 9% if passed in their current form. Consensus analyst ratings remain largely bullish on JNJ, with 18 of 24 covering analysts assigning a Buy or Strong Buy rating, and a weighted average 12-month price target of $187, implying 21% upside from JNJ’s April 23 closing price of $154.50. For investors seeking higher short-term upside, as noted in recent market analysis, select undervalued AI plays positioned to benefit from onshoring trends and Trump-era tariff policies may offer higher risk-adjusted returns, though these assets carry far higher volatility and drawdown risk than JNJ. Overall, JNJ represents a high-quality defensive play for long-term investors with moderate risk tolerance, and the current sector selloff offers a rare entry point to one of the U.S.’s most consistent operational performers. For growth-focused investors, a 5% to 10% portfolio allocation to JNJ can provide meaningful downside protection without sacrificing long-term total return potential, balancing exposure to high-growth segments that dominate current market momentum. (Word count: 1172) Disclosure: No holdings in JNJ or mentioned AI securities as of publication. Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryScenario planning is a key component of professional investment strategies. By modeling potential market outcomes under varying economic conditions, investors can prepare contingency plans that safeguard capital and optimize risk-adjusted returns. This approach reduces exposure to unforeseen market shocks.Global interconnections necessitate awareness of international events and policy shifts. Developments in one region can propagate through multiple asset classes globally. Recognizing these linkages allows for proactive adjustments and the identification of cross-market opportunities.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryAnalyzing intermarket relationships provides insights into hidden drivers of performance. For instance, commodity price movements often impact related equity sectors, while bond yields can influence equity valuations, making holistic monitoring essential.